Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Xutao Guo, Xiaolei Wei, Yongqiang Wei, Qi Wei, Ning Su, Yunxia Zhang, Haohao Lei, Ru Feng

Blood (2024) 144 (Supplement 1): 6776.

https://doi.org/10.1182/blood-2024-207666

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

Xiaolei Wei, Xutao Guo, Qi Wei, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 3121.

https://doi.org/10.1182/blood-2024-204940

Published: 2024

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2024-204915

Published: 2024

Journal Articles

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Yuqi Wang, Chen Huan, Zhang Hanzhen, Shanshan Zhang, Youhai Yuan, Ru Feng, Yongqiang Wei, Xiaolei Wei

Blood (2024) 144 (Supplement 1): 7031.

https://doi.org/10.1182/blood-2024-205810

Published: 2024

Journal Articles

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Zhang Hanzhen, Yongqiang Wei, Xiaolei Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 6456.

https://doi.org/10.1182/blood-2024-201377

Published: 2024

Journal Articles

Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

Menglin Li, HaiXia Fu, Hui Liu, Ru Feng, Yi Liu, Jingwen Wang, Lei Yang, Zhao Wang, Gaochao Zhang, Qingyuan Qu, Yuxiu Chen, Jianying Zhou, Mengyu Xiao, Lulu Wang, Mengtong Zang, Yun He, Xiaolu Zhu, Xiaosu Zhao, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 712.

https://doi.org/10.1182/blood-2024-198335

Published: 2024

Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2024) 144 (Supplement 1): 886.

https://doi.org/10.1182/blood-2024-198147

Published: 2024

Journal Articles

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Shenmiao Yang, Ru Feng, Xutao Guo, Zhenling Li, Qianqian Ju, Yujun Dong, Bingjie Wang, Yu Zhao, Liang Wang, Wanling Sun, Fang Fang, Liru Wang, Liping Su, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 7819.

https://doi.org/10.1182/blood-2024-210572

Published: 2024

Journal Articles

Polatuzumab Vedotin Plus Anti-CD20 Monoclonal Antibody and Dexamethasone in Previously Untreated Very Old/Frail Patients with Diffuse Large B-Cell Lymphoma

Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Weidong Ding, Xiaoxuan Xue, Haoyu Qin, Hongmei Jing, Hui Liu

Blood (2024) 144 (Supplement 1): 6521.

https://doi.org/10.1182/blood-2024-203031

Published: 2024

Journal Articles

Genetic Characteristics of Patients Aged ≥80 Years with Diffuse Large B-Cell Lymphoma

Xiaoya Yun, Jiefei Bai, Ru Feng, Hongmei Jing, Hui Liu

Blood (2024) 144 (Supplement 1): 6228.

https://doi.org/10.1182/blood-2024-207720

Published: 2024

Journal Articles

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Xutao Guo, Yunxia Zhang, Haohao Lei, Yongqiang Wei, Xiaolei Wei, Qi Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2024-201948

Published: 2024

Journal Articles

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Yutian Yang, Minglang Zhan, Zhang Hanzhen, Xiaolei Wei, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 6244.

https://doi.org/10.1182/blood-2024-198161

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax Combine Azacitidine for Acute Myeloid Leukemia in China: A Real-World Single-Center Study

Jiefei Bai, Hui Liu, Jiangtao Li, Ting Wang, Chunli Zhang, Yazi Yang, Xiaoya Yun, Jingjing Yin, Long Qian, Fei Zhao, Ru Feng, Hongmei Jing

Blood (2024) 144 (Supplement 1): 7896.

https://doi.org/10.1182/blood-2024-193714

Published: 2024

Journal Articles

Simplified Geriatric Assessment-Albumin: The Modified Tool for Older Diffuse Large B-Cell Lymphoma in China

Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Shuai Zhang, Qingyun Cao, Xiaoxuan Xue, Hongmei Jing, Hui Liu

Blood (2023) 142 (Supplement 1): 1769.

https://doi.org/10.1182/blood-2023-184522

Published: 2023

Journal Articles

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lyu, Cheng Fang, Sheng Xu, Jun Zhu

Blood (2023) 142 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2023-181352

Published: 2023

Journal Articles

Curcumin Enhances Ibrutinib Induced Killing Effect Against TP53-Mutated Chronic Lymphocytic Leukemia Cells in Vitro

Yunxia Zhang, Haohao Lei, Xiaolei Wei, Yongqiang Wei, Ru Feng, Xutao Guo

Blood (2023) 142 (Supplement 1): 5792.

https://doi.org/10.1182/blood-2023-179874

Published: 2023

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2023) 142 (Supplement 1): 6223.

https://doi.org/10.1182/blood-2023-182496

Published: 2023

Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2023-186252

Published: 2023

Journal Articles

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yu-Hua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2023-186099

Published: 2023

NARROW

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Polatuzumab Vedotin Plus Anti-CD20 Monoclonal Antibody and Dexamethasone in Previously Untreated Very Old/Frail Patients with Diffuse Large B-Cell Lymphoma

Genetic Characteristics of Patients Aged ≥80 Years with Diffuse Large B-Cell Lymphoma

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Efficacy and Safety of Venetoclax Combine Azacitidine for Acute Myeloid Leukemia in China: A Real-World Single-Center Study

Simplified Geriatric Assessment-Albumin: The Modified Tool for Older Diffuse Large B-Cell Lymphoma in China

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Curcumin Enhances Ibrutinib Induced Killing Effect Against TP53-Mutated Chronic Lymphocytic Leukemia Cells in Vitro

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only